Last reviewed · How we verify
PolyPEPI1018
At a glance
| Generic name | PolyPEPI1018 |
|---|---|
| Also known as | PolyPEPI1018 CRC vaccine |
| Sponsor | Treos Bio Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. (PHASE2)
- A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer (PHASE1)
- PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PolyPEPI1018 CI brief — competitive landscape report
- PolyPEPI1018 updates RSS · CI watch RSS
- Treos Bio Limited portfolio CI